Navigation Links
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Date:5/27/2009

A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is recommended when co-administered with a strong CYP3A4 inducer. Live vaccinations and close contact with those who have received live vaccines should be avoided by patients taking Afinitor. Afinitor should not be used in patients with severe hepatic impairment. Afinitor may cause fetal harm in pregnant women.

The most common adverse reactions irrespective of causality (incidence greater than or equal to 30%) were stomatitis, infections, asthenia, fatigue, cough and diarrhea. The most common grade 3/4 adverse reactions irrespective of causality (incidence greater than or equal to 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain and asthenia. The most common laboratory abnormalities (incidence greater than or equal to 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia and increased creatinine. The most common grade 3/4 laboratory abnormalities (incidence greater than or equal to 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia and hypercholesterolemia. Deaths due to acute respiratory failure (0.7%), infection (0.7%) and acute renal failure (0.4%) were observed in patients receiving Afinitor.

Femara important safety information

You should not take Femara if you are premenopausal. Your doctor should discuss the need for adequate birth control if you have the potential to become pregnant, if you are not sure of your postmenopausal status, or if you recently became postmenopausal. Femara is only indicated in postmenopausal women. Talk to your doctor if you're allergic to Femara or any of its ingredients. You should not take Femara if you are pregnant as it may cause fetal harm. Some women reported fatigue and dizziness with Femara. Until you know how it affects you, use caution before driving or operating machinery. Some patients taking Femara
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
2. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
3. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
4. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
5. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
8. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
9. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
10. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
11. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... , CAMBRIDGE, Mass., Oct. 14 Northern Light ( ... EBSCO Publishing (EBSCO) ( www.ebscohost.com ) that ... than 4,000 bio-pharmaceutical, health sciences and general business magazines, ... strategic research portals. SinglePoint users who also subscribe ...
... Luminous Medical, Inc. announced today that it has ... for exclusive rights to incorporate its glucose sensor into ... its monitor to enable clinicians to control hyperglycemia in ... was planning to use a sensing technology based on ...
Cached Medicine Technology:Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 2Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 3Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2
(Date:4/24/2014)... Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with ... contact lens-related infections, reports a study in Optometry ... American Academy of Optometry . The journal is published ... Wolters Kluwer Health . , Studies in animals and ... with the antimicrobial peptide melimine, according to the new research ...
(Date:4/24/2014)... be boring and irrelevant, could offer an alternative to ... Dr Milena Furtado, and her team from the Australian ... heart cell fibroblast is a close relative to a ... , In research published today in Circulation Research ... unique cells due to their genetic program, and will ...
(Date:4/24/2014)... in the world to discover a gene mutation in ... Ameloblastoma is an odontogenic tumour with a high tendency ... in the posterior of the lower jaw. Ameoloblastomas are ... the jaws as well as loss of several teeth. ... surgery and the recurrence of ameloblastoma, but finding such ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
... Goodwin HealthDay Reporter , WEDNESDAY, Feb. 9 ... cancer cell genome revealed never-before-seen changes in DNA that ... By mapping the full genetic blueprint of the tumor, ... development of more targeted drugs and a better understanding ...
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 9 ... than doubled the progression-free survival time for patients with ... new studies. In separate phase 3 trials by ... extended the survival of participants with advanced pancreatic neuroendocrine ...
... parks and recreation sites may be healthier, more physically ... to Penn State researchers. Investments in parks and recreational ... say Geof Godbey, professor emeritus of leisure studies, and ... "There is a strong relationship between how much money ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... diagnose heart disease, cancers, HIV and other diseases quickly ... The microsponges are an essential component of Rice University,s ... paper in the journal Small . ... Bioengineering and Chemistry, and his colleagues at Rice,s BioScience ...
... plan from an arm of the National Institutes of ... of most single-gene disorders and gaining new insights into ... to more accurate diagnoses, new drug targets and the ... therapeutic options, according to the plan from the National ...
Cached Medicine News:Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Key to better health care may be a walk in the park 2Health News:Not All Birthmarks Harmless, Expert Says 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4
The Precedent establishes a new generation of revision hip stems....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
...
...
Medicine Products: